British drugmaker AstraZeneca Plc said Ironwood Pharmaceuticals Inc would buy the US marketing rights for its newly-approved gout drug for up to $265 million.
The deal would give Ironwood the rights to sell the drug, Zurampic, which was approved in the United States last year to treat high levels of uric acid in the blood of patients suffering from gout.
AstraZeneca did not mention any upfront payment to be made by the U.S. drugmaker in its statement on Tuesday.
- (Reuters)
This article was corrected on Friday, May 6th
AstraZeneca to sell US rights for gout drug for up to $265m
Deal sees Ironwood Pharmaceuticals take on the rights to sell Zurampic
IN THIS SECTION
Garda hospitalised following Cork hit and run incident
Liverpool open up five-point lead at top of Premier League after Aston Villa win
Niall O’Callaghan stars as Cuala navigate late Naas comeback to reach Leinster semi-finals
Fine Gael’s 11% VAT plan branded ‘laughable’ as parties trade insults over election pledges
Israeli strikes kill at least 36 in Gaza and Lebanon as Qatar suspends mediation efforts
Business Today
Get the latest business news and commentary from our expert business team in your inbox every weekday morning